{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:38:36Z","timestamp":1787236716405,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.114007","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T04:59:28Z","timestamp":1710133168000},"page":"114007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A global phase II randomized trial comparing oral taxane ModraDoc006\/r to intravenous docetaxel in metastatic castration resistant prostate cancer"],"prefix":"10.1016","volume":"202","author":[{"given":"Ulka N.","family":"Vaishampayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5147-0641","authenticated-orcid":false,"given":"Marianne","family":"Keessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0552-6912","authenticated-orcid":false,"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth I.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6667-994X","authenticated-orcid":false,"given":"Tomas","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter F.","family":"\u00c1rkosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Cs\u00f6szi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Wiechno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Kopyltsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey V.","family":"Orlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Plekhanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Smagina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Varlamov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2024.114007_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2024.114007_bib2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114007_bib3","article-title":"Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population","author":"Freedland","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejca.2024.114007_bib4","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/PPA.S106629","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: A review of the literature","volume":"10","author":"Eek","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"10.1016\/j.ejca.2024.114007_bib5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ctrv.2010.04.005","article-title":"Anticancer oral therapy: Emerging related issues","volume":"36","author":"Banna","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.ejca.2024.114007_bib6","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/sj.bjc.6603059","article-title":"Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU\/LV in Dukes\u2019 C colon cancer: The X-ACT trial","volume":"94","author":"Cassidy","year":"2006","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.114007_bib7","first-page":"SP46","article-title":"Cost of home vs clinic administration of paclitaxel in metastatic breast cancer","volume":"27","author":"Sharma","year":"2021","journal-title":"Am J Manag Care"},{"issue":"2","key":"10.1016\/j.ejca.2024.114007_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12325-018-0861-3","article-title":"Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries","volume":"36","author":"de Freitas","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejca.2024.114007_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.euros.2021.10.003","article-title":"A Systematic Review of Patients\u2019 Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer","volume":"36","author":"Connor","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.ejca.2024.114007_bib10","first-page":"1","article-title":"Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey","author":"George","year":"2022","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.ejca.2024.114007_bib11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ijpharm.2016.07.068","article-title":"Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel","volume":"511","author":"Sawicki","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejca.2024.114007_bib12","article-title":"Modulation of Oral Bioavailability of Anticancer Drugs: From Mouse to Man","volume":"Vol 12","author":"Schellens","year":"2000","journal-title":"www elsevier nl\/locate\/ejps"},{"issue":"10","key":"10.1016\/j.ejca.2024.114007_bib13","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/ijc.27912","article-title":"P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel","volume":"132","author":"Hendrikx","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2024.114007_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114636","article-title":"The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins","volume":"162","author":"Loos","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"10.1016\/j.ejca.2024.114007_bib15","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-08-2944","article-title":"Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors","volume":"15","author":"Oostendorp","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114007_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejca.2017.09.010","article-title":"A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir","volume":"86","author":"de Weger","year":"2017","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.ejca.2024.114007_bib17","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1158\/1078-0432.CCR-17-2299","article-title":"A phase i dose escalation study of once-weekly oral administration of docetaxel as ModraDoc001 capsule or ModraDoc006 tablet in combination with ritonavir","volume":"25","author":"de Weger","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2024.114007_bib18","first-page":"1","article-title":"ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006\/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study","volume":"4","author":"Vermunt","year":"2021","journal-title":"Cancer Rep"},{"issue":"12","key":"10.1016\/j.ejca.2024.114007_bib19","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114007_bib20","first-page":"9716","article-title":"Effect of ademetionine on cytochrome P450 isoforms activity in rats","volume":"8","author":"Tong","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"8","key":"10.1016\/j.ejca.2024.114007_bib21","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US Prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.ejca.2024.114007_bib22","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1007\/s12325-022-02073-w","article-title":"Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan","volume":"39","author":"Leith","year":"2022","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.ejca.2024.114007_bib23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clgc.2021.07.009","article-title":"Beyond frontline therapy with abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: a real-world US study","volume":"19","author":"Shore","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"38","key":"10.1016\/j.ejca.2024.114007_bib24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1200\/EDBK_200967","article-title":"Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment","author":"Hahn","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejca.2024.114007_bib25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.urology.2017.08.067","article-title":"Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study","volume":"113","author":"Wallis","year":"2018","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ejca.2024.114007_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.54457\/DR.202201001","article-title":"Oral Versus Intravenous Chemotherapy in COVID-19 Epidemic","volume":"2","author":"Xiao","year":"2022","journal-title":"Dis Res"},{"issue":"17","key":"10.1016\/j.ejca.2024.114007_bib27","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1002\/cam4.3314","article-title":"Strategies for selecting\/switching chemotherapy and supportive care treatments during COVID-19 outbreak","volume":"9","author":"Li","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2024.114007_bib28","first-page":"74","article-title":"Real-World Utilization and Outcomes of Docetaxel among Older Men with Metastatic Prostate Cancer: A Retrospective Population-Based Cohort Study in Canada","volume":"Vol 26","author":"Shayegan","year":"2023"},{"issue":"5","key":"10.1016\/j.ejca.2024.114007_bib29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.47102\/annals-acadmedsg.V46N5p195","article-title":"Outcomes of Dose-Attenuated Docetaxel in Asian Patients with Castrate-Resistant Prostate Cancer","volume":"46","author":"Ang","year":"2017","journal-title":"Ann Acad Med Singap"},{"issue":"4","key":"10.1016\/j.ejca.2024.114007_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/ajco.12874","article-title":"Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-na\u00efve prostate cancer: The first real-life experience in Asia","volume":"14","author":"Poon","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114007_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18084266","article-title":"Medication experience and adherence to oral chemotherapy: a qualitative study of patients\u2019 and health professionals\u2019 perspectives","volume":"18","author":"Talens","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"10.1016\/j.ejca.2024.114007_bib32","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11845-019-02125-1","article-title":"Pharmacokinetic enhancers (cobicistat\/ritonavir) and the potential for drug-drug interactions","volume":"189","author":"Hollywood","year":"2020","journal-title":"Ir J Med Sci"},{"issue":"5","key":"10.1016\/j.ejca.2024.114007_bib33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/M22-0281","article-title":"Prescribing Nirmatrelvir\u2013Ritonavir: How to Recognize and Manage Drug\u2013Drug Interactions","volume":"175","author":"Marzolini","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:10:09Z","timestamp":1727395809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924001631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":33,"alternative-id":["S0959804924001631"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A global phase II randomized trial comparing oral taxane ModraDoc006\/r to intravenous docetaxel in metastatic castration resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114007"}}